Veru Inc (VERU)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.64-0.38%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · VERU
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 | Sep 2015 | Sep 2014 | Sep 2013 | Sep 2012 | Sep 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | — | — | 16.9 | 16.3 | 39.4 | 61.3 | 42.6 | 31.8 | 15.9 | 13.7 | 22.1 | 32.6 | 24.5 | 31.5 | 35.0 | 18.6 |
| Total Revenues | — | — | — | 16.3 | 39.4 | 61.3 | 42.6 | 31.8 | 15.9 | 13.7 | 22.1 | 32.6 | 24.5 | 31.5 | 35.0 | 18.6 |
| Cost of Revenues | — | — | 11.0 | 8.7 | 8.8 | 13.3 | 11.8 | 10.1 | 7.1 | — | — | — | — | — | — | — |
| Gross Profit | — | — | 5.9 | 7.6 | 30.6 | 47.9 | 30.8 | 21.7 | 8.8 | 7.0 | 13.3 | 19.0 | 13.1 | 17.5 | 20.6 | 9.9 |
| Operating Expenses & Income | ||||||||||||||||
| Selling, General & Admin | — | — | 31.2 | 48.1 | 43.2 | 20.7 | 14.5 | 14.3 | 14.8 | 11.5 | 8.7 | 12.1 | 9.1 | 7.5 | 9.6 | 6.5 |
| R&D Expenses | 11.8 | 15.6 | 12.8 | 51.2 | 70.9 | 32.7 | 16.9 | 13.7 | 10.9 | 3.1 | 0.1 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating Income | (19.2) | (24.8) | (36.9) | (93.8) | (83.5) | 13.0 | (14.7) | (6.4) | (20.9) | (8.5) | 3.0 | 6.6 | 3.9 | 9.8 | 10.9 | 3.3 |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | — | 0.6 | 2.4 | 4.4 | 4.9 | 4.6 | 4.7 | 3.0 | — | — | — | — | — | — | — |
| Other Non-Operating Income / Expenses | 5.1 | 9.1 | (0.2) | 1.1 | (0.3) | (8.7) | (5.3) | (5.9) | (2.2) | (0.1) | (0.2) | 0.1 | 0.0 | 0.1 | — | — |
| EBT, Incl. Unusual Items | — | — | — | (92.7) | (83.8) | 4.3 | (20.1) | (12.3) | (23.1) | (8.6) | 2.8 | 6.7 | 4.0 | 9.9 | 10.8 | — |
| Income Tax Expense | — | — | 0.7 | 0.5 | 0.2 | (3.1) | (1.1) | (0.3) | 0.9 | (2.0) | 2.5 | 2.3 | 1.5 | (4.4) | (4.5) | (2.2) |
| Net Income | ||||||||||||||||
| Net Income | (13.6) | (22.7) | (37.8) | (93.2) | (84.0) | 7.4 | (19.0) | (12.0) | (23.9) | (6.6) | 0.3 | 4.3 | 2.4 | 14.3 | 15.3 | 5.4 |
| Per Share | ||||||||||||||||
| Basic EPS | (0.59) | (1.55) | (0.28) | (1.10) | (1.05) | 0.10 | (0.28) | — | — | (0.25) | 0.01 | 0.15 | 0.09 | 0.51 | 0.55 | 0.20 |
| Diluted EPS | — | — | — | (1.10) | (1.05) | 0.09 | (0.28) | — | — | (0.25) | 0.01 | 0.15 | 0.08 | 0.50 | 0.53 | 0.19 |
| Dividend per Share | — | — | — | — | — | — | — | — | — | — | 0.21 | 0.21 | 0.21 | 0.26 | — | — |
| Basic Weighted Avg Shares | 23.1 | 14.6 | 134.9 | 85.0 | 80.1 | 76.3 | 66.8 | — | — | 34.6 | 28.7 | 28.5 | 28.5 | 28.4 | 27.7 | 27.3 |
| Diluted Weighted Avg Shares | — | — | — | 85.0 | 80.1 | 83.8 | 66.8 | — | — | 34.6 | 28.9 | 28.9 | 28.9 | 28.7 | 28.9 | 29.0 |
| Supplemental | ||||||||||||||||
| EBITDA | — | (24.6) | (36.6) | (93.5) | — | — | — | — | (20.7) | (8.2) | 3.4 | 7.1 | 4.5 | 10.3 | 11.4 | 3.8 |
| EBIT | (19.2) | (24.8) | (36.9) | (93.8) | (83.5) | 13.0 | (14.7) | (6.4) | (20.9) | (8.5) | 3.0 | 6.6 | 3.9 | 9.8 | 10.9 | 3.3 |
| Effective Tax Rate | — | — | — | -0.5% | -0.3% | -73.4% | 5.4% | 2.5% | -3.8% | 23.1% | 87.7% | 35.0% | 38.5% | -44.4% | -41.8% | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.